Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Biodefense Market

ID: MRFR/MED/52056-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

US Biodefense Market Research Report: Size, Share, Trend Analysis By Applications (Biological Threat Detection, Medical Countermeasures, Decontamination), By Product Type (Vaccines, Diagnostics, Therapeutics, Personal Protective Equipment), By End-use (Government, Military, Healthcare, Research Institutions), and By Technology (Genetic Engineering, Nanotechnology, Biomanufacturing) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Biodefense Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Biological Threat Detection
  50.     4.1.2 Biological Threat Response
  51.     4.1.3 Biodefense Research
  52.     4.1.4 Biodefense Training
  53.   4.2 Healthcare, BY End Use (USD Billion)
  54.     4.2.1 Government Agencies
  55.     4.2.2 Military
  56.     4.2.3 Healthcare Institutions
  57.     4.2.4 Research Laboratories
  58.   4.3 Healthcare, BY Product Type (USD Billion)
  59.     4.3.1 Vaccines
  60.     4.3.2 Diagnostic Kits
  61.     4.3.3 Protective Equipment
  62.     4.3.4 Decontamination Solutions
  63.   4.4 Healthcare, BY Technology (USD Billion)
  64.     4.4.1 Molecular Diagnostics
  65.     4.4.2 Immunoassays
  66.     4.4.3 Next Generation Sequencing
  67.     4.4.4 Bioinformatics
  68.   4.5 Healthcare, BY Funding Source (USD Billion)
  69.     4.5.1 Government Funding
  70.     4.5.2 Private Sector Investment
  71.     4.5.3 International Aid
  72.     4.5.4 Public-Private Partnerships
  73. 5 SECTION V: COMPETITIVE ANALYSIS
  74.   5.1 Competitive Landscape
  75.     5.1.1 Overview
  76.     5.1.2 Competitive Analysis
  77.     5.1.3 Market share Analysis
  78.     5.1.4 Major Growth Strategy in the Healthcare
  79.     5.1.5 Competitive Benchmarking
  80.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  81.     5.1.7 Key developments and growth strategies
  82.       5.1.7.1 New Product Launch/Service Deployment
  83.       5.1.7.2 Merger & Acquisitions
  84.       5.1.7.3 Joint Ventures
  85.     5.1.8 Major Players Financial Matrix
  86.       5.1.8.1 Sales and Operating Income
  87.       5.1.8.2 Major Players R&D Expenditure. 2023
  88.   5.2 Company Profiles
  89.     5.2.1 Emergent BioSolutions (US)
  90.       5.2.1.1 Financial Overview
  91.       5.2.1.2 Products Offered
  92.       5.2.1.3 Key Developments
  93.       5.2.1.4 SWOT Analysis
  94.       5.2.1.5 Key Strategies
  95.     5.2.2 Battelle Memorial Institute (US)
  96.       5.2.2.1 Financial Overview
  97.       5.2.2.2 Products Offered
  98.       5.2.2.3 Key Developments
  99.       5.2.2.4 SWOT Analysis
  100.       5.2.2.5 Key Strategies
  101.     5.2.3 L3Harris Technologies (US)
  102.       5.2.3.1 Financial Overview
  103.       5.2.3.2 Products Offered
  104.       5.2.3.3 Key Developments
  105.       5.2.3.4 SWOT Analysis
  106.       5.2.3.5 Key Strategies
  107.     5.2.4 Northrop Grumman (US)
  108.       5.2.4.1 Financial Overview
  109.       5.2.4.2 Products Offered
  110.       5.2.4.3 Key Developments
  111.       5.2.4.4 SWOT Analysis
  112.       5.2.4.5 Key Strategies
  113.     5.2.5 Raytheon Technologies (US)
  114.       5.2.5.1 Financial Overview
  115.       5.2.5.2 Products Offered
  116.       5.2.5.3 Key Developments
  117.       5.2.5.4 SWOT Analysis
  118.       5.2.5.5 Key Strategies
  119.     5.2.6 Boeing (US)
  120.       5.2.6.1 Financial Overview
  121.       5.2.6.2 Products Offered
  122.       5.2.6.3 Key Developments
  123.       5.2.6.4 SWOT Analysis
  124.       5.2.6.5 Key Strategies
  125.     5.2.7 General Dynamics (US)
  126.       5.2.7.1 Financial Overview
  127.       5.2.7.2 Products Offered
  128.       5.2.7.3 Key Developments
  129.       5.2.7.4 SWOT Analysis
  130.       5.2.7.5 Key Strategies
  131.     5.2.8 Smiths Group (GB)
  132.       5.2.8.1 Financial Overview
  133.       5.2.8.2 Products Offered
  134.       5.2.8.3 Key Developments
  135.       5.2.8.4 SWOT Analysis
  136.       5.2.8.5 Key Strategies
  137.   5.3 Appendix
  138.     5.3.1 References
  139.     5.3.2 Related Reports
  140. 6 LIST OF FIGURES
  141.   6.1 MARKET SYNOPSIS
  142.   6.2 US MARKET ANALYSIS BY APPLICATION
  143.   6.3 US MARKET ANALYSIS BY END USE
  144.   6.4 US MARKET ANALYSIS BY PRODUCT TYPE
  145.   6.5 US MARKET ANALYSIS BY TECHNOLOGY
  146.   6.6 US MARKET ANALYSIS BY FUNDING SOURCE
  147.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  148.   6.8 RESEARCH PROCESS OF MRFR
  149.   6.9 DRO ANALYSIS OF HEALTHCARE
  150.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  151.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  152.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  153.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  154.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  155.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  156.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
  157.   6.17 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
  158.   6.18 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
  159.   6.19 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  160.   6.20 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
  161.   6.21 HEALTHCARE, BY FUNDING SOURCE, 2024 (% SHARE)
  162.   6.22 HEALTHCARE, BY FUNDING SOURCE, 2024 TO 2035 (USD Billion)
  163.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  164. 7 LIST OF TABLES
  165.   7.1 LIST OF ASSUMPTIONS
  166.     7.1.1
  167.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  168.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  169.     7.2.2 BY END USE, 2026-2035 (USD Billion)
  170.     7.2.3 BY PRODUCT TYPE, 2026-2035 (USD Billion)
  171.     7.2.4 BY TECHNOLOGY, 2026-2035 (USD Billion)
  172.     7.2.5 BY FUNDING SOURCE, 2026-2035 (USD Billion)
  173.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  174.     7.3.1
  175.   7.4 ACQUISITION/PARTNERSHIP
  176.     7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Biological Threat Detection
  • Biological Threat Response
  • Biodefense Research
  • Biodefense Training

Healthcare By End Use (USD Billion, 2026-2035)

  • Government Agencies
  • Military
  • Healthcare Institutions
  • Research Laboratories

Healthcare By Product Type (USD Billion, 2026-2035)

  • Vaccines
  • Diagnostic Kits
  • Protective Equipment
  • Decontamination Solutions

Healthcare By Technology (USD Billion, 2026-2035)

  • Molecular Diagnostics
  • Immunoassays
  • Next Generation Sequencing
  • Bioinformatics

Healthcare By Funding Source (USD Billion, 2026-2035)

  • Government Funding
  • Private Sector Investment
  • International Aid
  • Public-Private Partnerships

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions